All Stories

  1. Unconventional mechanism of action and resistance to rapalogs in renal cancer

    Article • Proceedings of the National Academy of Sciences, June 2024, Proceedings of the National Academy of Sciences

    Dr. James Brugarolas

  2. Safety and efficacy of concurrent immune checkpoint inhibitors and hypofractionated body radiotherapy

    Article • OncoImmunology, February 2018, Taylor & Francis

    Dr. James Brugarolas

  3. Targeting Renal Cell Carcinoma with a HIF-2 antagonist

    Article • Nature, September 2016, Nature

    Dr. James Brugarolas

  4. Fibroblast Growth Factor Receptor-Dependent and -Independent Paracrine Signaling by Sunitinib-Resistant Renal Cell Carcinoma

    Article • Molecular and Cellular Biology, May 2016, ASM Journals

    Dr. James Brugarolas

  5. Platelet-Derived Growth Factor/Vascular Endothelial Growth Factor Receptor Inactivation by Sunitinib Results in Tsc1/Tsc2-Dependent Inhibition of TORC1

    Article • Molecular and Cellular Biology, July 2013, ASM Journals

    Dr. James Brugarolas